


Diarylamides as anti-cancer agent: A Literature Review

Aya abdulhamid, Even Ghassan, Omayma Alzoubi

Under Supervision of

Dr. Mohammed El-Gamal



Highlights:

- Imatinib, dasatinib and nilotinib are diarylamide-based drugs proven to treat CML through inhibiting BCR-ABL tyrosine kinase.
- Binding mode, pharmacokinetics, in vivo/in vitro tests, side effects, resistance studies and clinical trials of the three drugs has been reviewed.
- Newer diarylamides that was proven to be good as lead compound for development of anti-cancer agents are discussed.